

# Cquence

## AML/MDS Genotyping Panel

### Test type

NGS panel test

### Background

Cquence AML/MDS Genotyping Panel delivers information on predictive and prognostic mutations which are commonly involved in acute myelogenous leukemia and myelodysplasias. This panel is also designed to screen for mutations, such as *KRAS*, that may directly related to targeted or non-targeted treatment options.

The panel has a sensitivity of ~5 % mutant allele with strict next-generation sequencing quality control parameters.

### Test specifications

Test code	Methodology	Specimen requirements	Turnaround time
OKA	Next-generation sequencing supplemented with Sanger sequencing	6 mL blood in EDTA tube	10-14 days

### Genes targeted (43 genes)

*ABL1, ASXL1, BCOR, CBL, CBL-B, CEBPA, CREBBP, CSF3R, DNMT3A, ETV6, EZH2, FBXW7, FLT3, GATA1, GATA2, HRAS, IDH1, IDH2, IKZF1, IL7R, JAK1, JAK2, JAK3, KDM6A/UTX, KIT, KRAS, MLL, MPL, NOTCH1, NPM1, NRAS, PAX5, PTPN11, RUNX1, SF3B1, SRSF2, STAT3, SUZ12, TET2, TP53, U2AF35, WT1 and ZRSR2*